Key result
Cardiac resynchronization therapy in adult congenital heart disease significantly reduced QRS duration (-23.1 ms; 95% CI -31.6 to -14.7), improved systemic ventricular function, and reduced NYHA class.
Why the study?
Does cardiac resynchronization therapy improve electrocardiographic, functional, and clinical outcomes in patients with adult congenital heart disease?
Meta-Analysis (n=796)
Does cardiac resynchronization therapy improve electrocardiographic, functional, and clinical outcomes in patients with adult congenital heart disease?
Mean Difference: -23.1 (95% CI -31.6–-14.7)
In patients with adult congenital heart disease, cardiac resynchronization therapy is associated with significant improvements in QRS duration, systemic ventricular function, and NYHA class, including in those with a systemic right ventricle.
BACKGROUND: Patients with adult congenital heart disease (ACHD) often develop heart failure (HF). Cardiac resynchronization therapy (CRT) may provide benefit, but evidence is limited to observational studies and guidelines are extrapolated from acquired HF. OBJECTIVE: This study aimed to systematically evaluate the effects of CRT in ACHD, including both biventricular pacing (BiV) and conduction system pacing (CSP) strategies, on electrocardiographic, functional, and clinical outcomes. METHODS: We conducted a systematic review and meta-analysis following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines (PROSPERO CRD420251036152). PubMed, Embase, Web of Science, CINAHL, and Cochrane were searched until February 2025. Primary outcomes were changes in QRS duration, systemic ventricular function (SVF), and New York Heart Association (NYHA) class; secondary outcomes were HF hospitalizations and all-cause mortality. RESULTS: 25 studies (n = 796; 723 BiV, 73 CSP) were included. CRT was associated with significant QRS duration reduction (-23.1 ms; 95% confidence interval -31.6 to -14.7), SVF improvement (+7.8%; 5.9-9.6), and NYHA class reduction (-0.9; -1.2 to -0.5). Benefits extended to patients with a systemic right ventricle (QRS -27.7 ms; SVF +8.5%; NYHA -1.0). Pooled incidence rates of HF hospitalization and mortality were 4.3 and 3.2 per 100 patient-years, respectively. Early data suggest that CSP achieves comparable QRS narrowing with BiV, although long-term outcomes remain scarce. CONCLUSION: CRT in ACHD is associated with significant improvements in electrocardiographic, functional, and clinical outcomes, including patients with a systemic right ventricle. Although most evidence pertains to BiV, early reports on CSP are encouraging. Prospective, phenotype-specific studies with standardized outcomes are needed to optimize patient selection and pacing strategies.
No takes yet. Share an insight, caveat, or question.
Zwaenepoel et al. (2026) conducted a meta-analysis in Adult congenital heart disease (ACHD) (n=796). Cardiac resynchronization therapy (CRT) was evaluated on changes in QRS duration (MD -23.1 ms, 95% CI -31.6 to -14.7). Cardiac resynchronization therapy in adult congenital heart disease significantly reduced QRS duration (-23.1 ms; 95% CI -31.6 to -14.7), improved systemic ventricular function, and reduced NYHA class.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: